Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Competitive antagonist of histamine at the H2 receptor on gastric parietal cells, reducing gastric acid secretion (basal and stimulated).
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
300 mg IV every 6-8 hours, or as a continuous IV infusion of 37.5 mg/hour (900 mg/day) for patients unable to take oral therapy.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life: approximately 2 hours in healthy adults; prolonged in renal impairment (up to 20 hours in anuria).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minor (approximately 10-15% as metabolites).
Category C
Category A/B
Electrolyte
Electrolyte